Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022 08:05 ET
|
Impel Pharmaceuticals
Trudhesa® TRx’s Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59% Over Q1 2022 to $2.8 Million Sales Force Expanded by 50% to Capitalize on Prescription Momentum and Market...
Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25
April 21, 2022 08:00 ET
|
Impel NeuroPharma
SEATTLE, April 21, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 24, 2022 08:00 ET
|
Impel NeuroPharma
Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021 Planned Initiation of INP105 Proof-Of-Concept Study...
Impel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of Neurology
March 22, 2022 08:00 ET
|
Impel NeuroPharma
New Data Suggests Rapid, Sustained, and Consistent Migraine Relief with Trudhesa Treatment New Analysis Considers Efficacy of Trudhesa After Variety of Acute Therapies Post Hoc Pivotal Trial Data...
Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences
February 28, 2022 08:00 ET
|
Impel NeuroPharma
SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights
January 18, 2022 08:05 ET
|
Impel NeuroPharma
Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range Achieved Broad and Favorable...
Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021 08:00 ET
|
Impel NeuroPharma
Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adults Mobilized 60-Person Salesforce with a Targeted...
Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference
November 09, 2021 08:00 ET
|
Impel NeuroPharma
SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...
Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
November 08, 2021 08:00 ET
|
Impel NeuroPharma
SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...
Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine
September 28, 2021 08:30 ET
|
Impel NeuroPharma
Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space ...